RSV Vaccine Reduces Infant Severe Disease Risk During Pregnancy
“`html
RSV Vaccines Recommended and Found Safe, Effective
Table of Contents
Recent findings and recommendations highlight teh growing importance of Respiratory Syncytial virus (RSV) vaccination, particularly for older adults and infants. This article summarizes the latest developments as of September 30, 2025.
What is RSV?
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild,cold-like symptoms. However, it can be serious, especially for infants, young children, and older adults. RSV often leads to bronchiolitis and pneumonia, requiring hospitalization. According to the Centers for Disease Control and Prevention (CDC), RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lungs) in infants under 1 year of age.
Recent Findings on RSV Vaccine Safety and Effectiveness
A recent Cochrane review confirms that RSV vaccines are both safe and effective. The review analyzed data from multiple clinical trials and found a meaningful reduction in RSV-related hospitalizations and severe illness among vaccinated individuals. This provides strong evidence supporting the widespread use of RSV vaccines.
recommendations for RSV Vaccination
In Limerick, Ireland, the RSV program is now recommended for individuals over 65 years of age. Limerick’s Live 95 reports that this recommendation aims to protect vulnerable seniors during the upcoming RSV season.The recommendation is based on the positive results from clinical trials and the potential to significantly reduce the burden of RSV-related illness in this age group.
The CDC recommends RSV vaccination for adults 60 years and older, based on shared clinical decision-making wiht their healthcare provider. They also recommend RSV immunization for certain infants, including those born during or entering their first RSV season. Further details on infant vaccination recommendations can be found on the CDC website.
Who is at Risk from RSV?
While most people experience mild symptoms, certain groups are at higher risk of severe RSV illness:
- Infants and young children: Especially those under 6 months of age.
- Older adults: Those 65 years and older.
- Individuals with weakened immune systems: Due to underlying medical conditions or medications.
- Individuals with chronic heart or lung conditions: Such as asthma or COPD.
Timeline of RSV Vaccine Development
The development of RSV vaccines has been a decades-long effort. Here’s a brief timeline: